Robert Wood Johnson Hamilton and the Rutgers Cancer Institute of New Jersey welcome breast surgeon Firas Eladoumikdachi, MD to the team.
Robert Wood Johnson (RWJ) Hamilton and the Rutgers Cancer Institute of New Jersey (CINJ) recently received an accreditation by the National Accreditation Program for Breast Centers (NAPBC), a program administered by the American College of Surgeons.
Centers accredited by the NAPBC undergo a rigorous evaluation of their performance in the areas of: clinical management, research, community outreach, professional education, leadership and quality improvement.
The accreditation was coordinated by Thomas Kearney MD and Pauline Lerma MD. Dr. Kearney is the Chief of the Section of Breast Surgery at Rutgers CINJ and Robert Wood Johnson Medical School. He is a fellowship trained surgical oncologist on staff at RWJ Hamilton. Dr. Pauline Lerma is an Assistant Professor of Medicine at Rutgers CINJ and Robert Wood Johnson Medical School. She is a board certified medical oncologist and the medical director of the RWJ Hamilton breast consultation program.
At the same time, the centers have welcomed breast surgeon Firas Eladoumikdachi, MD to their breast cancer care team.
A fellowship-trained surgeon, Dr. Eladoumikdachi comes to RWJ Hamilton from Ohio where he previously served as the director of the breast program at Genesis Health Care System and vice chair of Ohio Integrated Care Providers.
Dr. Eladoumikdachi completed his fellowship in breast surgery at the Lynn Sage Comprehensive Breast Center at Northwestern University in Chicago and his residency in general surgery at Baylor College of Medicine in Houston.
He specializes in the treatment of benign and malignant tumors of the breast with a focus on breast conserving surgical techniques along with minimally invasive breast biopsy and sentinel node biopsy. Working with colleagues from plastic surgery, he performs immediate breast reconstruction when more extensive surgery is needed. He also evaluates patients at increased risk for the development of breast cancer due to family history or atypical findings at breast biopsy.
